Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus toripalimab for stage I/II extranodal NK/T-cell lymphoma with poor response to chemotherapy
ChiCTR2400091323Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL), sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete response rate. Started Oct 2024; status: completed.
02
Drugs
toripalimab
03
Conditions
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
Beyond the preview
Go deeper on ChiCTR2400091323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091323.